Clene Q4 2023 Earnings Report

Clene EPS Results

• Actual EPS: -$1.20
• Consensus EPS: -$1.40
• Beat/Miss: Beat by +$0.20
• One Year Ago EPS: N/A

Clene Revenue Results

• Actual Revenue: $0.17 million
• Expected Revenue: $0.14 million
• Beat/Miss: Beat by +$30.00 thousand
• YoY Revenue Growth: N/A

Clene Announcement Details

• Quarter: Q4 2023
• Date: 3/13/2024
• Time: N/A

Clene (NASDAQ:CLNN), a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.